BillionToOne, Inc. 8K

BillionToOne, Inc. announced strong second quarter 2026 results with a return to profitability, reiterated its 2026 revenue guidance, and detailed upcoming product launches and clinical validation for its prenatal and oncology testing platforms.

On August 5, 2026, BillionToOne, Inc. reported its unaudited financial results for the quarter ended June 30, 2026, showing a 64% year-over-year increase in total revenue to $109.4 million, improved gross margin to 70%, and a shift to $8.1 million in net income from a small loss in the prior-year period, driven by higher test volumes and average selling prices in both prenatal and oncology testing. The company reiterated its full-year 2026 revenue guidance of $450–$465 million and stated it expects to sustain profitability at current levels while continuing significant investments. BillionToOne also highlighted operating milestones including the upcoming August 17, 2026 commercial launch of an expanded 130-gene Unity Fetal Risk Screen panel, the planned September 1, 2026 commercial availability of Northstar Origin as an add-on tissue-of-origin feature to its Northstar Select oncology test, and newly published peer‑reviewed data validating its Northstar Response test as a strong predictor of survival in advanced solid tumor patients receiving immunotherapy.

Filing Facts

CIK

2070849

Ticker

-

Form

8K

Source Type

sec

Accession

0002070849-26-000048

Alert Tier

7